Eli Lilly and Company LLY
announced today the decision to stop ongoing clinical studies investigating
pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients
suffering from schizophrenia. The decision was made after a recently conducted
independent futility analysis concluded HBBN, the second of Lilly's two
pivotal studies, was unlikely to be positive in its primary efficacy endpoint
if enrolled to completion. The decision was not based on any safety signals.
Additionally, the recently completed Phase II study, HBCO, which investigated
pomaglumetad methionil as an adjunctive treatment with atypical
antipsychotics, did not meet its primary endpoint.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in